ViiV Healthcare ranked #1 for eleventh consecutive year in PatientView’s ‘Corporate Reputation of Pharma’ survey

We are delighted to be ranked as the number one pharmaceutical company for the eleventh consecutive year in PatientView’s ‘Corporate Reputation of Pharma – from the ‘Patient Perspective 2023 - 2024’ survey – as assessed by patient groups working with our company and also by patient organisations 'familiar' with us.

We are committed to living our mission to leave no person living with HIV behind and ultimately end the HIV epidemic – this means listening to the community, understanding their needs and working together to fight HIV and HIV-related stigma. We are grateful for the close collaboration and support of HIV-related patient groups in advancing the dialogue and ensuring that HIV remains a health priority.

In 2023, we made progress in addressing health inequalities by partnering with and funding community-led initiatives to improve health outcomes. As an example, ViiV, GSK and the Global Fund announced a three-year partnership and £6 million Gender Equality Fund to support local interventions to tackle gender-related inequalities for girls and women.

HIV-related stigma continues to be a significant barrier to the HIV response and is an area of continued focus for us. We leveraged digital innovations to share lived experiences as a means to address stigma. Last year, we launched a virtual reality immersive experience ‘Chapters of Stigma’ that allows viewers to experience the struggles and stigma people living with HIV frequently endure. This technology was brought to major public engagements and has served as a powerful tool to ignite conversation, dismantle stigmatising behaviours and create a more supportive environment.

We also continue to champion community-led advocacy and public policy engagement to ensure HIV remains a public health priority. For example, we supported the Transmasculine Working Group on HIV which developed policy tools and best practice guides to help governments and NGOs to include transgender men in their guidelines. These guides have been recognised by the World Health Organization and UNAIDS.

There is much work still to do, but we are optimistic that working with community partners, together we can end the HIV epidemic and address HIV-related stigma and discrimination.
Finally, we would like to thank everyone who took the time to participate and share their views in the survey, which we will continue to use to keep us accountable to our mission. We look forward to continuing our collaboration with you.

Harmony P. Garges, MD, Chief Medical Officer, ViiV Healthcare

Media contacts

For our corporate press office, email: Rachel Jaikaran

OR call +44 7823 523 755

For US-specific media enquiries,email: Audrey Abernathy

OR call +1 919 605 4521

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.